依折麦布与辛伐他汀联合用药（益适纯）对比阿托伐他汀治疗高胆固醇血症患者的剂量比较研究：益适纯对比阿托伐他汀（VYVA）研究 - Suppr | 超能文献

Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) Study.

作者信息

Galin Ira D, Smith Donald A

出版信息

Am Heart J. 2006 May;151(5):e1. doi: 10.1016/j.ahj.2005.10.009.

DOI:10.1016/j.ahj.2005.10.009

Abstract

摘要

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1

Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) Study.依折麦布与辛伐他汀联合用药（益适纯）对比阿托伐他汀治疗高胆固醇血症患者的剂量比较研究：益适纯对比阿托伐他汀（VYVA）研究

Am Heart J. 2006 May;151(5):e1. doi: 10.1016/j.ahj.2005.10.009.

2

Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study).依折麦布/辛伐他汀与阿托伐他汀对高胆固醇血症合并代谢综合征患者的调脂疗效及安全性比较（来自VYMET研究）

Am J Cardiol. 2009 Jun 15;103(12):1694-702. doi: 10.1016/j.amjcard.2009.05.003.

3

Safety and efficacy of ezetimibe/simvastatin combination versus atorvastatin alone in adults ≥65 years of age with hypercholesterolemia and with or at moderately high/high risk for coronary heart disease (the VYTELD study).依泽替米贝/辛伐他汀联合治疗与阿托伐他汀单药治疗在≥65 岁伴有高胆固醇血症且伴有或处于中等/高度冠心病风险的成人中的安全性和有效性（VYTELD 研究）。

Am J Cardiol. 2010 Nov 1;106(9):1255-63. doi: 10.1016/j.amjcard.2010.06.051.

4

Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study).依泽替米贝/辛伐他汀或阿托伐他汀治疗代谢综合征伴或不伴动脉粥样硬化性血管疾病患者时特定 LDL 胆固醇、非高密度脂蛋白胆固醇载脂蛋白 B 和高敏 C 反应蛋白水平的达成（来自 VYMET 研究）。

J Clin Lipidol. 2011 Nov-Dec;5(6):474-82. doi: 10.1016/j.jacl.2011.06.004. Epub 2011 Jun 15.

5

Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study).阿托伐他汀与辛伐他汀、普伐他汀、洛伐他汀及氟伐他汀治疗高胆固醇血症患者的比较剂量疗效研究（CURVES研究）

Am J Cardiol. 1998 Aug 1;82(3):406-7.

6

Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study.依折麦布与辛伐他汀联合用药（益适纯）对比阿托伐他汀治疗高胆固醇血症患者的剂量比较研究：益适纯对比阿托伐他汀（VYVA）研究

Am Heart J. 2005 Mar;149(3):464-73. doi: 10.1016/j.ahj.2004.11.023.

7

[Target values are more often attainable. Almost doubly so many patients with values under 100mg/dl].目标值往往更容易实现。几乎有两倍之多的患者数值低于100毫克/分升。

MMW Fortschr Med. 2004 Oct 28;146(44):57.

8

Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels.依折麦布/辛伐他汀与辛伐他汀及阿托伐他汀在降低C反应蛋白和低密度脂蛋白胆固醇水平方面的效果比较。

Am J Cardiol. 2007 Jun 15;99(12):1706-1713. doi: 10.1016/j.amjcard.2007.01.062. Epub 2007 May 2.

9

Did a flawed study design affect the results of the VYTAL study?有缺陷的研究设计是否影响了VYTAL研究的结果？

Mayo Clin Proc. 2007 Apr;82(4):521-2; author reply 522. doi: 10.4065/82.4.521-a.

10

Ezetimibe/simvastatin 10/40 mg versus atorvastatin 40 mg in high cardiovascular risk patients with primary hypercholesterolemia: a randomized, double-blind, active-controlled, multicenter study.依折麦布/辛伐他汀 10/40 毫克与阿托伐他汀 40 毫克在原发性高胆固醇血症的高心血管风险患者中的比较：一项随机、双盲、阳性对照、多中心研究。

Lipids Health Dis. 2012 Jan 31;11:18. doi: 10.1186/1476-511X-11-18.

引用本文的文献

1

Statin versus ezetimibe-statin for incident atrial fibrillation among patients with type 2 diabetes mellitus with acute coronary syndrome and acute ischemic stroke.他汀类药物与依折麦布-他汀类药物在 2 型糖尿病合并急性冠状动脉综合征和急性缺血性脑卒中患者中的新发心房颤动。

Medicine (Baltimore). 2023 Jun 9;102(23):e33907. doi: 10.1097/MD.0000000000033907.

2

Similar major cardiovascular outcomes between pure statin and ezetimibe-statin in comparable intensity for type 2 diabetes with extremely atherosclerotic risks.在 2 型糖尿病伴极高动脉粥样硬化风险患者中，他汀类药物与依折麦布联合他汀类药物的降脂强度相当时，纯他汀类药物与依折麦布联合他汀类药物的主要心血管结局相似。

Sci Rep. 2021 Mar 23;11(1):6697. doi: 10.1038/s41598-021-86090-9.

3

Impact of ezetimibe on atherosclerosis: is the jury still out?依折麦布对动脉粥样硬化的影响：尚无定论？

Mayo Clin Proc. 2009 Apr;84(4):353-61. doi: 10.1016/S0025-6196(11)60545-4.